Waldencast Acquisition Corp. a skin care company, provides advanced skin care treatments. Its products are designed to help minimize the appearance of premature skin aging, skin damage, hyperpigmentation, acne, and sun damage primarily available through dermatologists, plastic surgeons, medical spas, and other skin care professionals. Its portfolio includes Obagi Medical that provides transformational skin care products formulated to minimize signs of skin aging, address dark spots, hyperpigmentation, fine lines, and wrinkles and to protect and enhance skin tone and texture; and Obagi Clinical that offers skin care products designed to prevent the early signs of skin aging. The company was founded in 1988 and is based in White Plains, New York.

Waldencast plc

Waldencast is a self-described global beauty and wellness multi-brand platform.

Waldencast

Waldencast is a holding company and investment fund that incubates and accelerates early stage beauty and wellness brands and helps them rapidly create scale and profitability via industry specific operational expertise. Waldencast invests in brand-led business models and goes beyond traditional incubation and acceleration to develop a collective of innovative and unique brands that place responsible entrepreneurship at the heart of its operations.  Waldencast has offices in New York and London and has an investment portfolio in North America, Europe, and Latin America.

The selection of brands to participate in the community is as much driven by the strength of the brand concept and business model as it is by our shared human and social values: sustainability, responsibility, inclusivity.  We believe brands that marry purpose, art, beauty, and design with industry and commerce to make the planet and the lives of those in it better.

Individuals that are part of the Waldencast collective are as much driven by the strength of the brands’ ideas, as it is by sharing our dreamer/maker values: ambition with humility, idealism with practicality, grit with empathy, vision with action.

We have the spirit of a challenger, a disruptor, a game-changer. We are a start-up and we intend to stay in the attitude of a start-up regardless of our success.

Costa Brazil

2024 AWARD WINNING BROW SERUM🎉

InStyle has recognized Obagi Nu-Cil™ Eyebrow Boosting Serum as the Best Brow Serum in their Best Beauty Buys 2024 product roundup! 

“I was introduced to this powerhouse brow serum by board-certified dermatologist Mona Gohara, M.D.  …So it's safe to say I'm hooked.” writes Kara Jillian Brown

Thank you to our Obagi Fam and healthcare providers for the continuous love you show our products.

Visit your Obagi provider to learn more about this great product! 
#obagi #obagimedical #obagiskincare

Read the full article here:
https://lnkd.in/giiJuG-M

We're #hiring a new Amazon Brand Manager in Greater London, England. Apply today or share this post with your network.

Congratulations to our portfolio company C16 Biosciences for this recognition!

We are excited to participate in TD Cowen’s 8th annual conference 2024 with Oliver Chen, CFA and Jonna Kim, CFA.

We’re #hiring a new Glaze North America Key Account Director in United States. Apply today or share this post with your network.

	Dec '20	Dec '21	Dec '22	Dec '23
net income	-2.37M -	-19.58M 725.99%	-116.62M 495.75%	-89.98M 22.85%
depreciation and amortization	13.42M -	13.90M 3.60%	35.17M 152.96%	60.50M 72.01%
deferred income tax	-3.04M -	9.37M 407.95%	-5.73M 161.16%	-7.02M 22.47%
stock based compensation		-1.90M -	-64.73M 3,306.74%	9.23M 114.27%
change in working capital	-16.24M -	588K 103.62%	-33.12M 5,732.65%	95K 100.29%
accounts receivables	-16.66M -	-5.06M 69.65%	3.58M 170.89%	-2.89M 180.53%
inventory	4.44M -	-6.01M 235.33%	-6.63M 10.25%	-1.30M 80.38%
accounts payables	-7.39M -	9.65M 230.52%	8.66M 10.26%	4.03M 53.47%
other working capital	3.38M -	2.01M 40.50%	-38.74M 2,029.08%	254K 100.66%
other non cash items	798K -	1.14M 42.73%	100.02M 8,681.30%	127.79M 27.76%
net cash provided by operating activities	-7.43M -	3.53M 147.49%	-85.01M 2,509.01%	-29.77M 64.98%
investments in property plant and equipment	-1.71M -	-1.29M 24.60%	-2.50M 93.94%	-2.05M 18.03%
acquisitions net			-587.66M -
purchases of investments
sales maturities of investments			44.88M -	52K 99.88%
other investing activites		-2.50M -		52K -
net cash used for investing activites	-1.71M -	-3.79M 121.85%	-545.28M 14,298.63%	-1.99M 99.63%
debt repayment	-18.37M -	-116.45M 533.94%	-182.35M 56.58%	-21.93M 87.98%
common stock issued				70M -
common stock repurchased
dividends paid	-2.04M -	-2M 2.15%
other financing activites	34.73M -	123.62M 255.91%	451M 264.84%	66.25M 85.31%
net cash used provided by financing activities	14.32M -	5.16M 63.95%	633.35M 12,169.43%	44.33M 93.00%
effect of forex changes on cash		-32K -	-6.34M 19,709.38%	-147K 97.68%
net change in cash	5.18M -	4.87M 5.96%	-3.28M 167.34%	12.41M 478.33%
cash at beginning of period	3.39M -	8.57M 152.79%	13.44M 56.84%	10.16M 24.40%
cash at end of period	8.57M -	13.44M 56.84%	10.16M 24.40%	22.58M 122.14%
operating cash flow	-7.43M -	3.53M 147.49%	-85.01M 2,509.01%	-29.77M 64.98%
capital expenditure	-1.71M -	-1.29M 24.60%	-2.50M 93.94%	-2.05M 18.03%
free cash flow	-9.14M -	2.24M 124.53%	-87.51M 4,003.21%	-31.82M 63.64%

NASDAQ:WALD

Waldencast

Last Close

3.47

26/07 20:00

Market Cap

456.93M

Beta: -

Volume Today

73.17K

Avg: 5.58K

PE Ratio

−2.75

PFCF: 366.52

Preview